source
- Summit Therapeutics' ivonescimab misses interim goal, shares tumble 27% as trial setback raises doubtsSummit Therapeutics reported that its experimental immunotherapy ivonescimab failed to achieve statistical significance at an interim analysis of the late-stage HARMONi-3 trial in frontline non‑sma…
- FDA approves Axsome Therapeutics' Auvelity for Alzheimer’s agitationThe U.S. Food and Drug Administration has granted approval to Axsome Therapeutics’ oral medication Auvelity for the treatment of agitation in patients with Alzheimer’s disease. Axsome noted that a…